🔗 Share this article

While the US proceeds with sweeping adjustments to its immunization recommendations, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by questioning coronavirus vaccines during the global health crisis and has zeroed in on alleged deaths following Covid immunization in her short time at the FDA.

Scheduled Shifts to Pediatric Immunization Schedule

Public health authorities had intended to announce radical revisions to the childhood vaccine schedule earlier this month, aligning the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US out of alignment with much of the international standard with no evidence for improved outcomes. The planned update has been delayed until the next year.

Instead of Vinay Prasad, Dr. Høeg is listed to speak at the event. She was newly appointed acting director of the FDA’s CDER, the fifth person to head the division this calendar year.

A Shift at the Agency

This interim role might represent a tighter collaboration between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad solidify control at the FDA – and it suggests a renewed priority upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has often pushed for ending certain childhood vaccine recommendations in the US so as to align more in line with Denmark, a society with universal health coverage and a number of inhabitants roughly the population of the state of Wisconsin.

To date comments, she has persisted in emphasizing on vaccines – traditionally the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has no obvious experience in medication creation, approval processes or management, which has been standard for past heads of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“She appears not to have any of the qualifications” for leading the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in running a major agency. She is not an expert in drug approvals.”

Former heads of CBER would “grasp legal statutes and the research of drug development”, noted Janet Woodcock. “Objectively, she lacks the sort of resume that former directors who led the center have had.”

This division has an immense range of responsibilities at the agency, Woodcock pointed out.

“The public just zeroes in on the novel medication approvals, but the generic program authorizes numerous off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and more, and every single one have to be looked after,” she noted. “The thing you neglect, that is precisely what that I always told people is going to bite you.”

Additionally, a substantial administrative component to the position, which supervises more than 5,000 staff members. “It’s a enormous administrative position, if you execute it properly,” the former official concluded.

Official Statement and Disputed Policies

In response to inquiries about Høeg’s fitness for the role and whether this appointment indicates greater collaboration among FDA leaders on vaccines, a spokesperson said that the “inquiries stem from flawed presumptions”.

“Her experience is consistent with the responsibilities of her job,” the spokesperson explained, citing the time Dr. Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched fast-track approval initiative, a controversial rapid therapy clearance system that apparently worried her former heads. “By what process are these drugs being chosen for this expedited pathway? Who makes the choices?” Dr. Howard asked. “There is a lot of secrecy occurring at the agency right now.”

Overall, he stated, “the agency appears to be shifting towards more relaxed rules of all drugs, aside from vaccines.”

Established History on Immunizations

With vaccines, Høeg has a more established, if troubling, history, some experts said. She published a analysis using non-validated volunteer-provided data to assess the rate of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida top health official Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccinations are riskier than they are.

Included in her “wish list” for the current federal leadership encompassed altering regulations for new vaccines and halting “optional” immunizations, she said following the vote on a audio program. At the agency, Høeg has reportedly suggested excluding young men from receiving COVID-19 vaccinations.

“She is an thorough ideologue who begins with her preconceived notions and works backwards to accommodate the evidence in a highly disingenuous, fraudulent manner,” Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg joined other skeptics, {like|